Literature DB >> 845486

Effects of sulfinpyrazone on platelet prostaglandin synthesis and platelet release of serotonin.

M Ali, J W McDonald.   

Abstract

Sulfinpyrazone added to PRP inhibited the release of serotonin induced by collagen. The inhibitory effect depended strongly on the strength of the collagen stimulus. Serotonin release was also inhibited (up to 73%) in PRP prepared from subjects who had ingested the drug. This is the first demonstration of a direct effect of a sulfinpyrazone in vivo on in vitro tests of platelet function. Prostaglandin synthesis was studied with lysates of washed platelets, arachidonic acid-14C, and silicic acid chromatography to isolate a reaction product which was tentatively identified as thromboxane B2. Platelet prostaglandin synthesis was shown to be strongly inhibited by sulfinpyrazone. Inhibition was competitive with respect to substrate. It is proposed that effects of sulfinpyrazone on platelet function may be due to inhibition of prostaglandin synthesis. The competitive nature of sulfinpyrazone inhibition may explain why sulfinpyrazone is a strong inhibitor of the release reaction under conditions of dilute collagent stimulation but is weak in the presence of stronger stimuli. In comparing the potency of inhibitors of platelet prostaglandin synthesis the nature of inhibition must be considered. Competitive inhibitors may be incorrectly regarded as weak if studied only at high substrate concentration.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 845486

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  19 in total

1.  Sulphinpyrazone and the platelet serotoninergic mechanism in ischaemic heart disease.

Authors:  V K Puri; A Rawat; A Sharma; A Mehrotra; M Hasan; K Shanker; M Verma; J N Sinha; K P Bhargava
Journal:  Br Med J (Clin Res Ed)       Date:  1986-09-06

2.  Plasma levels of sulfinpyrazone and of two of its metabolites after a single dose and during the steady state.

Authors:  B Rosenkranz; C Fischer; P Jakobsen; A Kirstein Pedersen; J C Frölich
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 3.  Clinical pharmacokinetics and potentially important drug interactions of sulphinpyrazone.

Authors:  A K Pedersen; P Jakobsen; J P Kampmann; J M Hansen
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

4.  In vivo platelet aggregation in the rat: dependence on extracellular divalent cation and inhibition by nonsteroidal anti-inflammatory drugs.

Authors:  G Mallarkey; G M Smith
Journal:  Br J Pharmacol       Date:  1984-01       Impact factor: 8.739

5.  Effect of sulphinpyrazone on human platelet aggregation, 5-hydroxytryptamine release and adhesion ex vivo: comparison with naproxen.

Authors:  B Nunn; F J James
Journal:  Br J Clin Pharmacol       Date:  1980-03       Impact factor: 4.335

Review 6.  Prevention and management of gout.

Authors:  V L Star; M C Hochberg
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

7.  Effects of ischaemic heart disease, Crohn's disease and antimicrobial therapy on the pharmacokinetics of sulphinpyrazone.

Authors:  H A Strong; R Angus; J Oates; J Sembi; P Howarth; A G Renwick; C F George
Journal:  Clin Pharmacokinet       Date:  1986 Sep-Oct       Impact factor: 6.447

8.  The effect of oral administration of dipyrone on the capacity of blood platelets to synthesize thromboxane A2 in man.

Authors:  A Eldor; E Zylber-Katz; M Levy
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

9.  Sulphinpyrazone metabolism during long-term therapy.

Authors:  A K Pedersen; P Jakobsen
Journal:  Br J Clin Pharmacol       Date:  1981-06       Impact factor: 4.335

10.  Determination of sulfinpyrazone and four metabolites in plasma and urine by high pressure liquid chromatography.

Authors:  E G Lentjes; Y Tan; C A Van Ginneken
Journal:  Pharm Weekbl Sci       Date:  1985-12-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.